Aryeh Levenson, M.D. (ext 8597) March 26, 2012 SUBOXONE PROGRAM:
|
|
- Janel Turner
- 6 years ago
- Views:
Transcription
1 Aryeh Levenson, M.D. (ext 8597) March 26, 2012 SUBOXONE PROGRAM:
2 Opiate Addiction: History First seriously emerged iatrogenically with Civil War vets By late 19 th century, 2/3 of all those addicted were white middle-upper class Historically used for Menstrual symptoms Used as a cure in sanitoriums Above populations did not create social problem, but showed same characteristics of relapse/craving as current addicts
3 Opiate Addiction: history Heroine introduced 1898 as cough suppressant Hyperdermic technique introduced into medicine in 1910 s. Harrison Act of 1914: Restricted prescriptions of opiates for other than pain By 1920 s population of opiate addicts change: Now young immigrant males Crime rates skyrocket
4 Opiate Addiction - History 1929: Congress authorizes first treatment facilities Failure rates from 86%-97% During WWII (1940 s) numbers of addicts plummets due to disruption of shipping By 1960 s # s of addicts increase in inner cities and rise in white middle class Commitment laws enacted for addicts (up to 3 years). Same high failure rate
5 Opiate Addiction - history Civil Commitment Enacted due to fears about addiction related crimes Up to 3 years Very expensive, failure rates above 80% Discontinued
6 Opiate Addiction: History Numbers of addicts, associated crimes, and deaths skyrocket. E.gNYC: opiate related deaths #1 cause for year olds During Viet Nam 25%-50% of all soldiers developed an opiate addiction However, feared epidemic did not result upon their return 1980 s: 500,000 illicit opiate users 2000: 900,000 users
7 Origins of Buprenorphine (suboxone TX) Early Rationale: Extremely high rates of relapse led to search for alternative tx options Addicts universally reported severe cravings as cause Morphine, other short acting opiates high sedation, significant tolerance Methadone: 1960 s research indicated less euphoria, reduced cravings, no tolerance Supressed cravings for >24 hours
8 Origins of Buprenorphine (suboxone TX) 1965 first public Methadone program (NYC) Findings: reduction in relapse, better social outcomes, reduction in crime, increased employment. LAAM Levo-Alpha Acetyl Methadol Reduces cravings for hours or longer Became preferred maintenance therapy Due to cardiac side effects, largely discontinued
9 Opiate Replacement Therapy Methadone Studies going back to the 1970 s show that Methadone treatment much more successful than non opiate replacement therapy Reduction in rates of disease transmission, crime, child morbidity, etc. Thus, instituted as a public health measure
10 Origins of Buprenorphine (suboxone TX) 1980 s Naltrexone (opiate antagonist) studied Results: block all opiates Does not lower cravings High relapse rate due to poor compliance
11 Origins of Buprenorphine (suboxone TX) 1990 s Methadone maint. Tx demonstrated: Cost beneficial (tax payer savings of $4 for every dollar of cost Superior to all other forms of treatment: E.g outpatient, IOP, residential, civil commitment Better vocational rehab, reduction of cravings, reduction of relapse, reduction of crime, reduction of diversion, reduction of hospitalization
12 Origins of Buprenorphine (suboxone TX) Due to regulations, Methadone tx only available through highly specialized programs Institute of Medicine research Federal regulations of Methadone tx inhibited in availability of treatment
13 In Anchorage, these numbers are likely lower than the national average Dramatic increase of Heroine use throughout the USA and Alaska Only 15-20% opiate abusers receive treatment
14 Scope of the problem ~ ½ million opiate addicts in country Use highly associated with HIV, Hep B and C transmission Use associated with unemployment, criminality, childhood mental health issues, etc. Estimated opiate addiction costs> $5 billion to society Significant neonatal impact to developing fetus
15 Scope of Problem Opiates are leading cause of substance related deaths in USA Heroine users have up to 30X death rate as non heroine users In Anchorage opiate dependence related to increase rates of prostitution High percentage of pregnant opiate abusers Long term users develop abstinence Syndrome
16 Scope of the Problem Differential characteristics of opiate dependence Ultra high relapse rate due to physiological effects of chronic opiate use
17 Treatment Effectiveness Regrettably standard Psycho-social treatment is less effective for Opiate addicts than addicts of any other substance Relapse rate after psychosocial treatment completion tops 90% Due to Neurophysiological CNS changes induced by High dose Opiate use E.g. Chronic withdrawal/abstinent state
18 Impact of Methadone tx Methadone decreases mortality by 70% Addicts who drop out of methadone treatment have 8X risk of death compared with those remaining in treatment Reduction in HIV, Hep C transmission Improvement of a number of public health measures Suboxone use reduces mortality by 80% (France)
19 Problems with Methadone Maintenance Methadone still has high abuse potential Extremely high requirements for certification limits the program availability Requires specialty liscencing Anchorage Methadone program often has 1 year wait list Poor community acceptance
20 2000 Drug Addiction Treatment Act authorizes use of Opiate maintenance in physician offices by PCP s Increased Availability It will reach more people. Increased Accessibility It will allow treatment to occur in places other than specialized clinics. Better Overall Treatment It will allow simultaneous and improved treatment for other commonly co-occurring medical conditions, such as hepatitis C and HIV.
21 Thus legislation Regarding use of Suboxone
22 QUALIFYING UNDER THE ACT 1. Be a licensed physician 1. Complete the required training 2. Obtain a DEA waiver 3. Have available resources to refer to substance abuse programs 4. Treat up to 30 patients during the first year 5. May apply to treat up to 100 patients thereafter 6. (Group practice can combine total number of patients and divide by number of providers to maintain numbers
23 Opiate pharmacology Mu Receptors Activation analgesia, sleepiness, reduced awareness, respiratory depression, gastrointestinal depression, pupillaryconstriction, and euphoria. Mu receptor activation is also highly reinforcing physically and psychologically, and result in dependence. -morphine, heroin, methadone, levo-alpha-acetyl-methadol, hydromorphone, buprenorphine, hydrocodone, oxycodone, codeine, and fentanyl. Kappa Receptor activation activation of kappa receptors produces analgesia, dysphoriaand aversion Delta Receptors activation Less studied: mediate the emotional aspects of opioid addiction
24 Opiate Withdrawal symptoms Withdrawal symptoms includes restlessness, weakness, chills, body and joint pains, gastrointestinal cramps, anorexia (loss of appetite), nausea, feelings of inefficiency, and social withdrawal. Severe Cravings: Jonesing Signs of withdrawal: activation of the autonomic nervous system, lacrimation (tearing eyes), rhinorrhea(running nose), piloerection (gooseflesh), tachypnea(rapid breathing), mydriasis (dilated pupils), hypertension (high blood pressure), tachycardia (rapid heart beat), muscle spasms, twitching, restlessness, vomiting, and diarrhea.
25 Opiate Abstinence Syndrome Chronic Opiate Abstinence Syndrome: Less intense chronic feelings of withdrawal includes restlessness, weakness, chills, body and joint pains, gastrointestinal cramps, anorexia (loss of appetite), nausea, feelings of inefficiency, and social withdrawal. Chronic cravings
26 Tolerance Vs. Dependence Vs. Abuse Tolerance: require to take more of the medication to get same clinical effect Dependence: sudden discontinuation of medication results in withdrawal symptoms Addiction: Maladaptive behaviors around the use of the substance
27 Abuse/Dependence (NOT DSM IV) Abuse E.g. Neglect of responsibilities due to use of substance Use of substance in dangerous situations (e.g. driving under influence) Use of substance leads to illegal activities Use of substance results in maladaptive behavior changes Dependence includes the above AND Tolerance/dependence AND Cravings of substance not due to underlying medical condition (e.g. pain)
28 Drug Seeking Behavior Mistaking Legitimate Users for Drug Misusers Situations in which legitimate narcotic users can be misidentified as drug misusers. Pseudo-addiction: Patients whose pain is undertreated may exhibit drug-seeking behaviors ("doctor shopping," etc.) to relieve their pain. Since these behaviors are also common among drug-abusers, can be mistaken as as addiction. However, pseudo-addicted patients legitimately need more analgesics to adequately treat their pain, and their behavior will stop once pain is adequately treated.
29 Drug Seeking Behaviors Therapeutic Dependence: concern about losing or interrupting access to pain medication (e.g., by losing or changing medical insurance, changing doctors) leads to opiate seeking behaviors These patients may try to create an emergency supply of medication that can cause legitimate users to be mistaken for drug misusers.
30 Buprenorphine or bust.. Orwhy use buprenorphine rather than Methadone
31 Opiate pharmacology Agonist: binds to receptor and activates receptor to do all the fun stuff opiates do. Antangonist: bind to receptor but does not activate. Blocks agonists Partial agonist: Binds to receptor with activation at lower doses, but activation quickly plateaus
32
33 BUPRENORPHINE (SUBOXONE) Two formulations: (Schedule III) Buprenorphine alone: Subutex Partial Agonist (now in generic) Used primarily in pregnancy Buprenorphine + Naloxone (Suboxone) -4:1 RATIO Naloxone is antagonist
34 Buprenorphine Buprenophine is partial agonist Relatively long therapeutic half-life (24-60 hours) Relatively mild withdrawal syndrome Low risk of overdose Preferentially binds to mu receptors over other agonists limits mu receptor activation Blocks effects of other opiates
35 Buprenorphine Poorly bioavailability orally fair sublingual bioavailability Good IV bioavailability Versus: Naloxone an Opiate Antagonist Good IV bioavailability Poor oral and sublngual bioavailability Thus Abuse of Suboxone will precipiate withdrawal
36 SCF Suboxone program Philosophy: Based on research, not on theory NOT BASED ON ABSTINANCE MODEL E.g. use of opiate replacement treatment Risk reduction model E.g. THC use Relapses
37 SCF Buprenorphine Suboxone Program Screening R/O contraindications Referral Refer to Suboxone clinic Pre-induction Establish diagnoses, prepare to start Buprenorphine Induction Start the medication Stabilization Get customer s life stable Maintenance Primary care to prescribe Buprenorphine Discontinuation stopping the medication
38 SCF suboxone Program Screening stage To R/O contraindications prior to referral Medical Provider Component R/o contraindications Provide physical exam Assess for medical comorbidities (e.g. hepatitis, TB, STDs, HIV, Abcesses, pregnancy, endocarditis, renal/pulmonary disease, head trauma
39 SCF suboxone Program Screening stage Behavioral Health clinician Component Screen out major psychiatric comorbiditiesthat will require additional MH referral Assess for motivation Assess for reliability Preliminary Opiate abuse/dependence screening Meet diagnosis of Opiate Abuse/Dependence (ICD 9 or DSM IV) Physical tolerance and/or dependence Recurrent use resulting in maladaptive interpersonal, vocational, physical, legal, family functioning REMEMBER: Pseudoaddictionis not Opiate Dependence
40 SCF Suboxone Program Referral Stage All referrals will come through PCP Whether or not generated by customer, SCF clinics, outside providers, etc After Screen all referrals will go to either Bonny Hughes or Tiffany Dushkin
41 SCF Suboxone Program Clinic stage Pre-induction Done by Psychiatrist Pre-induction Psychiatric screen/mental status exam by psychiatrist Development of wellness plan Referral to substance abuse program (DAC, CITC, etc) Referral to Suboxone group (Michael Yates) Mental health, etc
42 SCF Suboxone Program Clinic stage Pre-induction Done by Psychiatrist, Suboxone Case manager Customer education Regarding opiate withdrawal Regarding use of Buprenorphine Regarding induction appointment Customer contract Lost/stolen RX s, early refills, pill counts, toxicology screens, diversion, etc Set up plan for WIthdrawaland induction appt.
43 SCF Suboxone Program Clinic Phase - Induction Establish in moderate severe opiate withdrawal Provide Buprenorphine dose Re-eval withdrawal symptoms ~Q hour and repeat Buprenorphine challenge until withdrawal complete Monitor for Precipitated withdrawal
44 SCF Suboxone Program Clinic Phase - Stabilization Done by Psychiatrist, substance abuse, clinic staff Monitor for Medication compliance Monitor for psychosocial treatment compliance (E.g. DAC, SuBoxone group, etc) Monitor for illicit substance abuse/diversion Pill counts, urine tox, urine Buprenorphine screens Monitor for abstinance symptoms Monitor medication Side effects Monitor psychosocial functional improvement Determine when sufficiently stable to refer back to primary care
45 Treatment Program 2X/week suboxone group. PRN meetings with Bonnie Hughes (case manager, exemplar) Community Support groups (mandatory) Establishment of community sober support system (mandatory) Pill Counts Tox and Buprenorphine Screens On going evaluation of THC, etoh use
46 Treatment Program Ongoing assessment of functionality and well being Integration of Mental Health Counseling Integration of psychiatric treatment On going dialogue regarding treatment response and limitations
47 Clinical Use of Buprenorphine Detoxification Determination made by customer unless breaks agreement > 90% relapse after taper Consider Naltrexone/Vivitrol
Opioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationModule II Opioids 101 Opiate Opioid
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module II Opioids 101 Module II Goals of the Module This module reviews the following:! Opioid addiction and the brain!
More informationOpioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationMethadone Maintenance 101
Methadone Maintenance 101 OTP/DAILY DOSING CLINICS - ANDREW PUTNEY MD Conflicts of Interest - Employed by Acadia HealthCare 1 Why Methadone? At adequate doses methadone decreases opioid withdrawal symptoms
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationMedication Assisted Treatment:
Medication Assisted Treatment: A Training For Multidisciplinary Addiction Professionals Module III Medications 101 Goals for Module III This module reviews the following: Overview of three medications
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationThe Opioid-Exposed Woman
The Opioid-Exposed Woman Management Considerations for Labor and Delivery Jane Sublette, MS, RN, CNM, WHNP-BC Fairview Ridges Hospital Objectives Describe opioid-associated risks to the mother and fetus
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationOptimizing Suboxone in Opioid Addicts
Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org
More informationTreating Opioid Use Disorders: An Update for Counselors and Other Providers
Treating Opioid Use Disorders: An Update for Counselors and Other Providers Brad Shapiro, MD Medical Director Opiate Treatment Outpatient Program Zuckerberg San Francisco General THE DOSING WINDOW HISTORICAL
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationOpioid Use in Pregnant Women and Prenatal Care. Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard
Opioid Use in Pregnant Women and Prenatal Care Murray F Dweck MD, FACOG Medical Director/OBGYN Florida Department of Health -Brevard Objectives Summarize contextual and co-morbid factors observed among
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationOverview of Opioid Use Disorder
Overview of Opioid Use Disorder Doug Burgess, MD Medical Director of Outpatient Services, Truman Medical Centers Assistant Professor of Psychiatry, University of Missouri- Kansas City Objectives History
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. A Treatment Improvement Protocol TIP
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction A Treatment Improvement Protocol TIP 40 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health
More informationOpioid Treatment in North Carolina SEPTEMBER 13, 2016
Opioid Treatment in North Carolina SEPTEMBER 13, 2016 Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2007 Source Where Respondent Obtained
More informationWasted AN INTRODUCTION TO SUBSTANCE ABUSE
Wasted AN INTRODUCTION TO SUBSTANCE ABUSE Dr. Brian L. Bethel Child and Family Therapist Independent Trainer and Consultant LPCC-S, LCDC III, RPT-S www.brianlbethel.com INTERPLAY COUNSELING & CONSULTING
More informationTHA Medication Safety Summit. Wesley Geminn, PharmD, BCPP
THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationAddressing Alaska s Opioid Epidemic From Understanding to Action
Addressing Alaska s Opioid Epidemic From Understanding to Action The opioid epidemic is devastating American families and communities. To curb these trends and save lives, we must help prevent addiction
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationMedical Assisted Treatment of Opioid
Medical Assisted Treatment of Opioid Dependence with XR-NTX(Vivitrol) Michael McNamara DO, FACN Medical Director Mental Health Center of Greater Manchester Manchester NH Outline Overview of Opioid Dependence
More informationSUBOXONE TREATMENT PROGRAM
SUBOXONE TREATMENT PROGRAM What is Suboxone? Suboxone is a medication used for the treatment of addiction to prescription pain medication, heroin addiction, methadone or other opioid dependence. The primary
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationMedication Assisted Treatment. Michael Palladini, RPh MBA CAC
Medication Assisted Treatment Michael Palladini, RPh MBA CAC palladini.michael@gmail.com History of MAT Addiction as a Disease The concept of addiction as a disease of the brain challenges deeply ingrained
More informationIdentification and Treatment of Opioid Use Disorders in Primary Care Settings
Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationOpioids. Sergio Hernandez, MD
Opioids Sergio Hernandez, MD Required Slide Disclosures 1. SIGNIFICANT FINANCIAL INTERESTS NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT 2. GENERAL AND OBLIGATION INTERESTS All general
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationMAT - ICAAD 2018 Ron Jackson, MSW, LICSW
The ATTC Network Ten Regional Centers northwest@attcnetwork.org www.attcnetwork.org/northwest phone. 206-685-4419 1107 NE 45 th St, Ste 120, Seattle, WA 98105 http://attcnetwork.org/northwest U.S. Opioid
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More informationTapering Opioids Best Practices*
Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand
More informationMethadone Treatment. in federal prison
INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional
More informationInterdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings
Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationBrief History of Methadone Maintenance Treatment
METHADONE Brief History of Methadone Maintenance Treatment Methadone maintenance treatment was on the cusp of the social revolution in the sixties. Doctors and public health workers had concluded what
More informationMethadone Maintenance
Methadone Maintenance A Practical Guide to Pharmacotherapy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Ron Joe, MD, DABAM Objectives I. Pharmacology Of Methadone II. Practical Application of Pharmacology
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationThe Social Worker s Role in Medication Assisted Treatment
The Social Worker s Role in Medication Assisted Treatment Rocky Ephraim Lucas, LICSW Behavioral Health Consultant, Kanawha City Health Center (Cabin Creek Health Systems) What is Medication-Assisted Treatment
More informationMethadone and Pregnancy
Methadone and Pregnancy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Charissa Patricelli, MD, CCFP, ABAM Clinical Associate Professor, Dept. of Family Practice UBC American Board of Addiction Medicine
More informationMethadone Treatment. in federal prison
INFORMATION FOR FEDERAL PRISONERS IN BRITISH COLUMBIA Methadone Treatment in federal prison This booklet will explain how to qualify for Methadone treatment in prison, the requirements of the Correctional
More informationMedication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 Amended Date: 10/1/2015 DRAFT Table of Contents
Medication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 10/1/2015 Table of Contents 1.0 Description of the Procedure, Product, or Service... 3 1.1 Definitions... 3 2.0 Eligibility Requirements...
More informationDisclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE
BUPRENORPHINE UPDATE Christian J. Teter, Pharm.D., BCPP Associate Professor, Psychopharmacology College Of Pharmacy, University Of New England Portland, ME E-Mail: cteter@une.edu Image Source: pubchem.ncbi.nlm.nih.gov
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationWR Fentanyl Symposium. Opioids, Overdose, and Fentanyls
Opioids, Overdose, and Fentanyls Outline: What are opioids? Why are we experiencing and opioid crisis? Potency, purity, and product How do opioids cause overdose and overdose deaths? What is naloxone and
More informationVivitrol Drug Court and Medication Assisted Treatment
Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment
More informationOpioid Use Disorder Treatment: Buprenorphine Treatment Basics
Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Daniel Warren, MD Eastern Oregon Coordinated Care Organization Provider Forum on Chronic Noncancer Pain Management Pendleton, OR February 24,
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More informationTrends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville
Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted
More informationJohn Murphy DO, MS Lynx Healthcare
Addiction to Pain Medication and Treatment John Murphy DO, MS Lynx Healthcare No Disclosures Objectives 1 Understand basic neurobiology and learning theory around opioid addiction 2 Identify aberrant behavior
More informationMEDICATION ASSISTED TREATMENT
MEDICATION ASSISTED TREATMENT MODULE 14 ALLIED TRADES ASSISTANCE PROGRAM PREVENTATIVE EDUCATION: SUBSTANCE USE DISORDER Medication Assisted Treatment Types of Medication Assisted Treatment: Methadone Naltrexone
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationOPIOID REPLACEMANT THERAPY: AN OVERVIEW
OPIOID REPLACEMANT THERAPY: AN OVERVIEW Matthew Felgus MD FASAM Matthew A Felgus, MD, FASAM mafelgus@wisc.edu matthewfelgusmd.com 6333 Odana Rd, Ste 3, Madison WI 53719 (608) 257-1581 Board Certified in
More informationFighting Today s Opioid Epidemic
Fighting Today s Opioid Epidemic Establish in 1966 as a Public Health Department Location: Rock Falls, IL/Whiteside County Population: Whiteside County 2015--57,079 Serving Rural IL: Primarily Whiteside,
More informationRecognizing Narcotic Abuse and Addiction and Helping Those With It
Recognizing Narcotic Abuse and Addiction and Helping Those With It Michael McNett, MD Medical Director for Chronic Pain Member, WI Med Society Opioid Subcommittee Ancient History 1995: OxyContin approved
More informationOPIATES AND ADDICTION MEDICATIONS. Dr. Carroll W. Thornburg, D.O Chief Medical Officer in Primary Care and Addiction Services
OPIATES AND ADDICTION MEDICATIONS Dr. Carroll W. Thornburg, D.O Chief Medical Officer in Primary Care and Addiction Services Dr. Carroll W. Thornburg, D.O Chief Medical Officer in Primary Care and Addiction
More informationOpioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.
Opioid Use Disorders as a Brain Disease Why MAT is so important Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of Social Work University of Washington Organization Name: CareOregon Course Title:
More informationOpioid Task Force Kick-Off Meeting. February 29, 2016
Opioid Task Force Kick-Off Meeting February 29, 2016 Scope of the Opioid Problem and Data Review Olivia Kasirye, MD, MS County Public Health Officer OVERVIEW The Opioid Epidemic Opioid Task Force Development
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More information3/26/14. Opiates PSY B396 ALCOHOL, ALCOHOLISM, & DRUG ABUSE. Early History Cont d. Early History. Opiate Use in the 19th century. Technology Advances
Opiates PSY B396 ALCOHOL, ALCOHOLISM, & DRUG ABUSE Chapter 10 Opiates The most dramatic example of the doubleedged sword character of drugs Most potent painkillers Prototype addictive drug: Heroin Early
More informationBuprenorphine Prescribing as a Patient- Centered Medical Home Enhancement
Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement TANNER NISSLY DO, BOB LEVY MD FASAM, MICHELE MANDRICH MSW, CMPE AS YOU ENTER, PLEASE SET UP TO PARTICIPATE IN OUR POLL EVERYWHERE
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More informationThe Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D.
The Unseen Consequences of Prescription Drug Abuse Stephen Loyd, M.D. Stephen Loyd, M.D. Receives no commercial support, in any form, from pharmaceutical companies or anyone else Medical Director for Substance
More informationInjectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP
Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report
More informationMaternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC
Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More informationTriage, Assessment and Treatment Planning
Triage, Assessment and Treatment Planning Prepared by Todd Sakakibara MD, CCFP, FCFP Clinical Assistant Professor, Dept. Family Practice UBC Diplomate of the American Board of Addiction Medicine Triage
More information